地诺单抗治疗在骨巨细胞瘤管理中的整合应用。
Integration of denosumab therapy in the management of giant cell tumors of bone.
作者信息
Miles Daniel T, Voskuil Ryan T, Dale Wood, Mayerson Joel L, Scharschmidt Thomas J
机构信息
Department of Orthopaedic Surgery, University of Tennessee College of Medicine Chattanooga, USA.
Division of Musculoskeletal Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Nationwide Children's Hospital, USA.
出版信息
J Orthop. 2020 Mar 28;22:38-47. doi: 10.1016/j.jor.2020.03.020. eCollection 2020 Nov-Dec.
Abstract
A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.
摘要
文献综述表明，地诺单抗在肿瘤学界越来越受到青睐，尤其是在骨巨细胞瘤（GCTB）中的使用频率不断增加。地诺单抗会成为GCTB治疗的突破吗？在此，我们提供一个相关病例实例，回顾关于地诺单抗用于GCTB的历史和基础科学的文献，强调治疗剂量和疗程的最新见解，并指出该领域的进展。
相似文献
1
Integration of denosumab therapy in the management of giant cell tumors of bone.
J Orthop. 2020 Mar 28;22:38-47. doi: 10.1016/j.jor.2020.03.020. eCollection 2020 Nov-Dec.
2
Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
Gulf J Oncolog. 2019 May;1(30):67-75.
3
Recommencement of Denosumab for Unresectable Giant Cell Tumor of the Cervical Spine: A Case Report.
Spine (Phila Pa 1976). 2018 May 1;43(9):E551-E556. doi: 10.1097/BRS.0000000000002440.
4
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Clin Cancer Res. 2012 Aug 15;18(16):4415-24. doi: 10.1158/1078-0432.CCR-12-0578. Epub 2012 Jun 18.
5
Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Ann Diagn Pathol. 2022 Apr;57:151882. doi: 10.1016/j.anndiagpath.2021.151882. Epub 2021 Dec 23.
6
Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
ESMO Open. 2020 Jul;5(4). doi: 10.1136/esmoopen-2019-000663.
7
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.
Cancers (Basel). 2022 May 4;14(9):2290. doi: 10.3390/cancers14092290.
8
Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020929786. doi: 10.1177/2309499020929786.
9
Updated concepts in treatment of giant cell tumor of bone.
Curr Opin Oncol. 2022 Jul 1;34(4):371-378. doi: 10.1097/CCO.0000000000000852.
10
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone.
Oncol Lett. 2016 Dec;12(6):4312-4318. doi: 10.3892/ol.2016.5246. Epub 2016 Oct 12.
引用本文的文献
1
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence.
Cancers (Basel). 2022 May 4;14(9):2290. doi: 10.3390/cancers14092290.
2
New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.
Molecules. 2021 Oct 27;26(21):6491. doi: 10.3390/molecules26216491.
3
A giant cell tumor of the bone in the rib cage left to proliferate unfettered for seven years to an extensive size.
Respir Med Case Rep. 2021 May 1;33:101419. doi: 10.1016/j.rmcr.2021.101419. eCollection 2021.
4
A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva) Related Osteonecrosis of the Jaw: A Retrospective Study.
J Clin Med. 2021 May 28;10(11):2390. doi: 10.3390/jcm10112390.
5
The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone.
World J Surg Oncol. 2021 Feb 2;19(1):37. doi: 10.1186/s12957-021-02143-3.
本文引用的文献
1
Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Med Mol Morphol. 2020 Mar;53(1):1-6. doi: 10.1007/s00795-019-00238-1. Epub 2019 Nov 20.
2
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Lancet Oncol. 2019 Dec;20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6.
3
The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics.
Calcif Tissue Int. 2019 Sep;105(3):239-251. doi: 10.1007/s00223-019-00573-6. Epub 2019 Jun 13.
4
Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
J Orthop Sci. 2020 May;25(3):513-519. doi: 10.1016/j.jos.2019.05.003. Epub 2019 May 30.
5
Bone metastasis: Interaction between cancer cells and bone microenvironment.
J Oral Biosci. 2019 Jun;61(2):95-98. doi: 10.1016/j.job.2019.02.002. Epub 2019 Mar 5.
6
Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.
Oncologist. 2019 Jul;24(7):889-e421. doi: 10.1634/theoncologist.2019-0280. Epub 2019 Apr 30.
7
A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.
Jpn J Clin Oncol. 2019 Apr 1;49(4):379-382. doi: 10.1093/jjco/hyz004.
8
Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Clin Orthop Relat Res. 2018 Sep;476(9):1783-1790. doi: 10.1007/s11999.0000000000000104.
9
Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
Bone Joint J. 2019 Feb;101-B(2):170-177. doi: 10.1302/0301-620X.101B2.BJJ-2018-0907.R2.
10
Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
J Bone Joint Surg Am. 2018 Mar 21;100(6):496-504. doi: 10.2106/JBJS.17.00057.
Zotero 插件